A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess the Efficacy and Safety of Daily OM-85 Treatment vs. Placebo given in Children Aged 6 Months to 5 Years with Recurrent Wheezing
The EAGLE (Efficacy Assessment in recurrent wheezinG chiLdrEn) Study is looking at how safe and effective a 6-month daily course of a study drug, Broncho-Vaxom, is for reducing the number of wheezing/asthma-like episodes (WEs) in young children who have recurrent wheezing.
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study with 6 month treatment phase and 6 month observation phase.
Child
1. Age range: 6 months to 72 months (5 years) 2. History of wheeze episodes
Treatment
National
Childrens Hospital Colorado
Andrew Liu, MD
Protocol Number: 23-0534
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers